Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients

• Status: Withdrawn
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate whether long-term rifaximin administration reduces spontaneous bacterial peritonitis recurrence rate in cirrhotic patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Ciprofloxacin; Rifamycins; Rifaximin

Criteria

Inclusion Criteria:

• Patients diagnosed with cirrhosis based on clinical, biochemical, ultrasonographic and/or histological criteria

• Patients who had recovered from an episode of spontaneous bacterial peritonitis

• Age > 18 and <80 years

Exclusion Criteria:

1. Decompensated cirrhotic patients with

• serum bilirubin > 3.2 mg/dL

• prothrombin time < 25%

• serum creatinine > 3 mg/dL

2. Active gastrointestinal bleeding

3. Hepatic encephalopathy > grade 2

4. Patients who have clinical, biochemical or radiological data suggesting hepatocellular carcinoma